Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299036 | 0.85 | TSHR (0.40) | TSHRPDE2ALMNATYRESR1 | |
| SCHEMBL3249831 | 0.79 | — | — | |
| SCHEMBL12024885 | 0.77 | TSHR (0.55) | TSHRLMNATYRHPGDHSD17B10 | |
| SCHEMBL95798 | 0.77 | ALDH1A1 (0.50) | TSHR | |
| SCHEMBL14703793 | 0.77 | ALDH1A1 (0.50) | TSHR | |
| SCHEMBL52644 | 0.77 | TSHR (0.55) | TSHRLMNATYRHPGDHSD17B10 | |
| SCHEMBL21497367 | 0.77 | HSD11B1 (0.39) | TSHRPDE2ALMNATYRESR1 | |
| SCHEMBL23794954 | 0.74 | TSHR (0.52) | TSHRLMNATYRHPGDHSD17B10 | |
| SCHEMBL8015827 | 0.74 | TSHR (0.60) | TSHR | |
| SCHEMBL14703788 | 0.74 | HSD11B1 (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | claimed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| WO-2024101402-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| WO-2024101386-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2022-01-27 | — | — | US | disclosed |
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-05-11 | — | — | US | disclosed |
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2020-09-24 | — | — | US | disclosed |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (BM) | 2020-03-10 | — | — | US | disclosed |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-05-21 | — | — | US | disclosed |
| US-20180346476-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-12-06 | — | — | US | disclosed |
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-06-21 | — | — | US | disclosed |
| EP-3303323-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196513-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016100349-A2 | BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PDE2A 4364/4885LMNA 4872/4885 |
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | TSHR 463/4885PDE2A 1469/4885LMNA 4638/4885 |
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | TSHR 463/4885PDE2A 1469/4885LMNA 4638/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | TSHR 3652/4885PDE2A 4737/4885LMNA 4722/4885 |
| US-20180346476-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | TSHR 454/4885PDE2A 1475/4885LMNA 4633/4885 |
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | TSHR 454/4885PDE2A 1475/4885LMNA 4633/4885 |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PDE2A 4364/4885LMNA 4872/4885 |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | TSHR 463/4885PDE2A 1469/4885LMNA 4638/4885 |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | TSHR 463/4885PDE2A 1469/4885LMNA 4638/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | TSHR 2043/4885PDE2A 1833/4885LMNA 1469/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PDE2A 4364/4885LMNA 4872/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PDE2A 4364/4885LMNA 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.